Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ODN/Pam2 - Pulmotect

Next Previous
Drug Profile

ODN/Pam2 - Pulmotect

Alternative Names: ODN-M362/Pam2CSK4; Pam2-ODN; Pam2/ODN; Pam2CSK4/ODN-M362; PUL-042

Latest Information Update: 16 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pulmotect
  • Developer Cancer Prevention & Research Institute of Texas; National Heart, Lung and Blood Institute; Pulmotect
  • Class Antineoplastics; Antisense oligonucleotides; Antivirals; Lipopeptides
  • Mechanism of Action Toll-like receptor 2 agonists; Toll-like receptor 6 agonists; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease; COVID 2019 infections; Lung disorders
  • No development reported Haematological malignancies; Pneumocystis pneumonia

Most Recent Events

  • 24 Apr 2025 Phase-II clinical trials in Lung disorders (Treatment-experienced) in USA (Inhalation) (NCT06665100)
  • 30 Oct 2024 Pulmotect plans a phase II trial in Lung disorders (Treatment-experienced) in USA (Inhalation) in October 2025 (NCT06665100)
  • 16 Oct 2024 Pharmacodynamics data from a preclinical trial in Lung disorders presented at the IDWeek 2024 (IDW-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top